Phase III study of single-dose casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting.
P. J. Hesketh
Consultant or Advisory Role - GlaxoSmithKline
V. Moiseyenko
No relevant relationships to disclose
G. Rosati
No relevant relationships to disclose
A. Makhson
Honoraria - Amgen; AstraZeneca; Lilly
J. Levin
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
M. W. Russo
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline